Novo Nordisk (NVO) Q1 2026 earnings review
Massive 340B Reversal Masks a Harsh Reversal in Underlying Growth
On paper, Novo Nordisk reported a spectacular 32% top-line surge and a 67% jump in Net Profit. In reality, these numbers are artificially inflated by a massive DKK 26.8 billion ($4.2B) one-time reversal of 340B rebate provisions. Stripping away this accounting noise reveals a starkly different story: underlying adjusted sales contracted by 4% in constant currency. The core issue is the U.S. market, where the new 'Most Favored Nations' (MFN) agreement has caused severe price erosion, completely overwhelming impressive volume gains from the new Wegovy pill launch. Management's guidance confirms the pain is structural, with 2026 adjusted sales expected to decline between 4% and 12%.
🐂 Bull Case
The oral Wegovy launch is breaking records, surpassing 2 million total prescriptions since its January launch and driving a massive 85% volume growth in the U.S. branded obesity market.
While the U.S. struggles with pricing, International Operations (IO) adjusted obesity sales surged 44%. EUCAN (+23%) and APAC (+22%) are proving that global appetite for GLP-1s is far from saturated.
🐻 Bear Case
Despite staggering prescription volumes, U.S. adjusted sales dropped 11%. The MFN agreement is destroying price realization faster than patient volume can compensate.
The foundational diabetes business is reversing. Global GLP-1 diabetes adjusted sales fell 11%, led by a 15% drop for Ozempic, indicating that the core portfolio is vulnerable to intense payer pressure and competition.
⚖️ Verdict: 🔴
Bearish. When a company experiences 85% market volume growth but reports a 11% decline in regional adjusted sales, the business model is under severe structural pressure. The pricing environment has permanently altered the growth trajectory.
Key Themes
Volume Boom Contradicts Revenue Reality
Management's narrative heavily emphasizes that 'Wegovy is driving a strong start' led by 'rapid adoption.' However, the underlying data directly contradicts this positive narrative. Despite the U.S. branded obesity market experiencing 85% volume growth, total U.S. adjusted sales reversed dramatically, falling 11%. The harsh reality is that aggressive U.S. pricing concessions—driven by the MFN agreement—have entirely decoupled prescription volume from revenue growth.
Wegovy Pill: The Ultimate Innovation Catalyst
The Wegovy pill represents a massive technological and commercial leap, defining a new category as the first oral peptide for obesity. Hitting >200,000 weekly prescriptions and generating DKK 2.25 billion in Q1 alone, it is successfully targeting the GLP-1-naive patient demographic and driving massive self-pay channel adoption. If cannibalization of the injectable franchise remains low, this is a structural growth vector.
U.S. Macro and Regulatory Squeeze
The macro-regulatory environment is permanently impairing U.S. profitability. The Most Favored Nations (MFN) agreement is aggressively forcing down net prices. Looking ahead, the company has preemptively announced massive WAC (list price) cuts of up to 50% for Wegovy taking effect in January 2027 to navigate the complexities of the U.S. rebate system. The era of unchecked U.S. margin expansion is over.
Core Diabetes Franchise is Reversing
The legacy diabetes business is showing severe signs of fatigue. Global GLP-1 diabetes adjusted sales fell 11% (U.S. down 16%). Ozempic sales declined 8% globally, and Rybelsus dropped 15% due to lower realized prices and a 'reprioritisation of promotional activities.' As the market shifts heavily toward obesity, the diabetes cash engine is sputtering.
International Operations: The New Growth Engine
With the U.S. market bogged down by pricing battles, International Operations (IO) is picking up the slack. IO adjusted sales grew 6%, driven by a 44% explosion in Obesity care. The company is leaning into this momentum by pushing Wegovy into over 55 countries and gaining regulatory flexibilities, like the EMA approval to store Wegovy at room temperature for up to 48 hours, vastly simplifying European distribution.
Pipeline Delivers High-Dose Efficacy
Novo Nordisk continues to innovate to protect its moat. The FDA approval and immediate U.S. launch of Wegovy HD (7.2 mg semaglutide) offers a compelling 20.7% mean weight loss, positioning it to compete aggressively against high-efficacy rivals like tirzepatide. Concurrently, the FDA approval of Awiqli creates a new standard of care in the diabetes space with once-weekly basal insulin.
China Decelerates Ahead of Generic Cliff
Adjusted sales in Region China fell 10%, heavily impacted by list price reductions implemented in late 2025. With semaglutide generics already launching in India and approved in Canada, the impending loss of exclusivity in China poses a significant mid-term threat to IO growth.
Other KPIs
Decelerating. Down significantly from 83.5% in Q1 2025. The 290 basis point compression is a direct result of lower realized U.S. prices and ongoing one-time manufacturing capacity expansion costs, confirming that the pricing headwinds are heavily impacting the bottom line.
Accelerating slightly from DKK 11.3 billion a year ago. The 13% increase is primarily driven by a planned moderation in capital expenditures (down 16% YoY to DKK 11.3B), providing ample liquidity to fund the massive DKK 15 billion share repurchase program.
Reversing. Decreased by 13% at constant currency. This decline is largely due to the structural savings from the 9,000-person headcount reduction executed in late 2025, alongside a reduction in legal provisions, shielding operating margins from further collapse.
Guidance
Decelerating. The midpoint of -8% implies that the underlying sales contraction seen in Q1 (-4%) will worsen as the year progresses. Management explicitly blames the U.S. MFN agreement and international semaglutide patent expiries.
Decelerating. Aligned directly with the top-line contraction. The fact that profit is not expected to fall faster than sales is a testament to the aggressive 2025 cost-cutting program and falling CapEx, which are successfully acting as a margin parachute.
Stable. The maintained robust cash generation is largely due to the forecasted decline in capital expenditures (expected around DKK 55B, down from DKK 60B in 2025) as the company moves past the peak of its global supply chain expansion cycle.
Key Questions
Wegovy Pill Cannibalization
With the Wegovy pill reaching over 200,000 weekly prescriptions, what percentage of this volume is genuinely expanding the market (GLP-1 naive patients) versus cannibalizing the higher-margin injectable Wegovy franchise?
The U.S. Pricing Floor
Given the 11% adjusted sales decline in the U.S. driven by the MFN agreement, and the planned 50% list price cut in January 2027, has the U.S. portfolio reached its net pricing floor, or should investors expect further structural erosion?
340B Reversal Mechanics
The DKK 26.8 billion reversal of 340B provisions massively distorted Q1 profitability. Is this strictly a one-time true-up for prior periods, or does it signal a permanent, structural reduction in ongoing 340B rebate exposure moving forward?
International Generic Cliff
With semaglutide generics now launched in India, approved in Canada, and looming in China, what is the modeled pace of market share erosion in International Operations over the next 12-24 months?